[go: up one dir, main page]

SV2002000092A - Polimorfos de un citrato de azobiciclo 2.2.2. oct-3-ilamina cristalino y sus composiciones farmaceuticas ref. pcl0414ajwa/bb - Google Patents

Polimorfos de un citrato de azobiciclo 2.2.2. oct-3-ilamina cristalino y sus composiciones farmaceuticas ref. pcl0414ajwa/bb

Info

Publication number
SV2002000092A
SV2002000092A SV2000000092A SV2000000092A SV2002000092A SV 2002000092 A SV2002000092 A SV 2002000092A SV 2000000092 A SV2000000092 A SV 2000000092A SV 2000000092 A SV2000000092 A SV 2000000092A SV 2002000092 A SV2002000092 A SV 2002000092A
Authority
SV
El Salvador
Prior art keywords
polymorphes
oct
citrate
crystalline
azobiciclo
Prior art date
Application number
SV2000000092A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000092A publication Critical patent/SV2002000092A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DOS FORMAS POLIMORFICAS CRISTALINAS DE CITRATO DE (2-BENZHIDRIL-1-AZO-BICICLO[2.2.2.]OCT-3-IL)-(5-ISOPROPIL-2-METOXIBENCIL)AMINA MONOHIDRATO (LOS MONOHIDRATOS) SON LA FORMA A Y LA FORMA B. LA COMPOSICION FARMACEUTICA QUE CONTIENE AL MENOS UNO DE ESTOS POLIMORFOS TIENE UNA ESTABILIDAD VENTAJOSA PARA LA FORMULACION PARA EL TRATAMIENTO DE EMESIS AGUDA EN PACIENTES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES CONVENCIONALMENTE ORAL, MEDIANTE PREFERIBLEMENTE COMPRIMIDOS O CAPSULAS, E INTRAVENOSA. SE DESCRIBE TAMBIEN UN PROCEDIMIENTO DE OBTENCION DE LAS FORMAS A Y B.
SV2000000092A 1999-06-01 2000-05-31 Polimorfos de un citrato de azobiciclo 2.2.2. oct-3-ilamina cristalino y sus composiciones farmaceuticas ref. pcl0414ajwa/bb SV2002000092A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
SV2002000092A true SV2002000092A (es) 2002-02-05

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000092A SV2002000092A (es) 1999-06-01 2000-05-31 Polimorfos de un citrato de azobiciclo 2.2.2. oct-3-ilamina cristalino y sus composiciones farmaceuticas ref. pcl0414ajwa/bb

Country Status (38)

Country Link
US (1) US6387925B1 (es)
EP (1) EP1181289A1 (es)
JP (1) JP2003501353A (es)
KR (1) KR20020005055A (es)
CN (1) CN1353712A (es)
AP (1) AP2001002350A0 (es)
AR (1) AR029753A1 (es)
AU (1) AU767331B2 (es)
BG (1) BG106139A (es)
BR (1) BR0011125A (es)
CA (1) CA2372236A1 (es)
CO (1) CO5170468A1 (es)
CR (1) CR6513A (es)
CZ (1) CZ20014270A3 (es)
DZ (1) DZ3051A1 (es)
EA (1) EA004206B1 (es)
EE (1) EE200100655A (es)
GT (1) GT200000086A (es)
HK (1) HK1046407A1 (es)
HN (1) HN2000000076A (es)
HR (1) HRP20010884A2 (es)
HU (1) HUP0201798A3 (es)
IL (1) IL145952A0 (es)
IS (1) IS6129A (es)
MX (1) MXPA01012328A (es)
NO (1) NO20015845L (es)
NZ (1) NZ514762A (es)
OA (1) OA11955A (es)
PA (1) PA8496001A1 (es)
PE (1) PE20010155A1 (es)
PL (1) PL352715A1 (es)
SK (1) SK17342001A3 (es)
SV (1) SV2002000092A (es)
TN (1) TNSN00119A1 (es)
TR (1) TR200103472T2 (es)
UY (1) UY26177A1 (es)
WO (1) WO2000073303A1 (es)
ZA (1) ZA200109839B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
EP1790635A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries, Inc. Processes for preparing amorphous fluvastatin sodium
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DK0587723T3 (da) * 1991-05-31 1996-04-01 Pfizer Quinuclidinderivater
JP2668164B2 (ja) * 1992-11-12 1997-10-27 ファイザー・インク． Ｐ物質拮抗薬としてのキヌクリジン誘導体
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
AR029753A1 (es) 2003-07-16
DZ3051A1 (fr) 2004-03-27
PA8496001A1 (es) 2002-07-30
PE20010155A1 (es) 2001-02-08
HUP0201798A3 (en) 2002-10-28
EE200100655A (et) 2003-02-17
NO20015845D0 (no) 2001-11-30
HN2000000076A (es) 2001-02-02
HK1046407A1 (zh) 2003-01-10
UY26177A1 (es) 2000-12-29
TNSN00119A1 (fr) 2005-11-10
NZ514762A (en) 2002-12-20
MXPA01012328A (es) 2002-07-30
NO20015845L (no) 2002-01-30
CZ20014270A3 (cs) 2002-08-14
OA11955A (en) 2006-04-13
JP2003501353A (ja) 2003-01-14
KR20020005055A (ko) 2002-01-16
AP2001002350A0 (en) 2001-12-31
PL352715A1 (en) 2003-09-08
SK17342001A3 (sk) 2002-10-08
GT200000086A (es) 2001-11-21
ZA200109839B (en) 2003-01-29
IS6129A (is) 2001-10-26
HUP0201798A2 (en) 2002-09-28
HRP20010884A2 (en) 2003-04-30
CR6513A (es) 2003-11-25
BG106139A (bg) 2002-05-31
EP1181289A1 (en) 2002-02-27
BR0011125A (pt) 2002-02-19
IL145952A0 (en) 2002-07-25
EA004206B1 (ru) 2004-02-26
AU767331B2 (en) 2003-11-06
WO2000073303A1 (en) 2000-12-07
TR200103472T2 (tr) 2002-05-21
US6387925B1 (en) 2002-05-14
EA200100982A1 (ru) 2002-06-27
CO5170468A1 (es) 2002-06-27
CN1353712A (zh) 2002-06-12
AU4424600A (en) 2000-12-18
CA2372236A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
EE04578B1 (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks
BR0015605A (pt) Composição e uso
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ATE429210T1 (de) Orale flüssige zusammensetzungen
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
AR027360A1 (es) Composicion farmaceutica
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
MX9300399A (es) Derivados heterotriciclicos.
SV2002000092A (es) Polimorfos de un citrato de azobiciclo 2.2.2. oct-3-ilamina cristalino y sus composiciones farmaceuticas ref. pcl0414ajwa/bb
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
SV2001000093A (es) Formas polimorfas de un citrato de azobiciclo 2,2,2, octan-3-amina y sus composiciones farmaceuticas ref.pcl0216/82962/bb
ES2184761T3 (es) Derivados de taxanos c10 y composiciones farmaceuticas.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ECSP003510A (es) Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas
AR033457A1 (es) Compuesto de piperazina, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para prepararlo
EE04872B1 (et) a-tsklodekstriini v?i selle derivaadi kasutamineLH-RH peptiidanaloogi sisaldavate farmatseutiliste kompositsioonide valmistamiseks ja a-tsklodekstriinil p?hinev farmatseutiline kompositsioon LH-RHpeptiidanaloogide peroraalseks manustamiseks